Bristol-Myers Squibb
275 S Bryn Mawr Ave, F18,
Bryn Mawr
PA
19010
United States
Tel: 269366-0681
154 articles with Bristol-Myers Squibb
-
Immuno-Oncology Sector Deals Dominate 2017 Life Sciences Deal of the Year Awards
3/7/2018
Bristol-Myers Squibb acquisition of IFM Therapeutics, and Amgen-CytomX licensing deal recognized among more than 4,000 transactions in annual Cortellis Deal of the Year Awards from Clarivate Analytics
-
IFM Therapeutics and Bristol-Myers Squibb Awarded 2017 Deal of the Year by Clarivate Analytics
3/7/2018
Deal of the Year Highlights Bristol-Myers Squibb's Acquisition of IFM's Preclinical STING and NLRP3 Agonist Programs
-
The possibility of a tax bill being passed has many investors and analysts forecasting 2018 to be a big year for mergers and acquisitions.
-
Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results From Phase 1/2 Study Evaluating the Combination of ADCETRIS (Brentuximab Vedotin) and Opdivo (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma
12/11/2017
The data were also simultaneously published online in the journal Blood.
-
Week in Review: China Life Science Deals Total $550M
12/11/2017
Pfizer acquired China/Asia rights for Cresemba, an antifungal drug developed by Swiss pharma Basilea, in a $226M deal.
-
Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments
12/6/2017
Under the terms of the license agreement, Ayala will have exclusive worldwide development and commercialization rights for BMS-906024 and BMS-986115, two gamma secretase inhibitors previously developed by BMS as a Notch inhibitor for oncology indications.
-
Bristol-Myers Squibb and Pfizer Alliance Urge People to ‘Tune in to AFib, Take Note of Stroke Risk’
12/5/2017
The Bristol-Myers Squibb and Pfizer Alliance, the National Stroke Association and iHeartMedia today launched ‘Tune in to AFib, Take Note of Stroke Risk’ to educate the estimated nearly seven million Americans in 2017 living with atrial fibrillation (AFib) not caused by a heart valve problem about their increased risk of stroke.
-
Bristol-Myers' Opdivo Demonstrates Superior Three-Year Survival Benefit for Patients With Previou...
11/6/2017
No new safety signals were identified and the data showed a safety profile consistent with two-year results. -
Bristol-Myers Squibb Presents Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
11/2/2017
Bristol-Myers Squibb today confirmed that 34 abstracts related to ORENCIA (abatacept) and the Company’s immunoscience pipeline
-
Bristol-Myers Squibb recognizes JLL for Service Delivery Excellence
11/1/2017
JLL has been recognized by global biopharmaceutical company Bristol-Myers Squibb with a Service Delivery Excellence Award announced at the company’s annual Global Suppliers Conference.
-
BioGeneration Ventures Fund III Reaches EUR 82 Million in Final Close
10/31/2017
Due to strong market interest, the fund has exceeded its original target of EUR 50 million.
-
Bristol-Myers Squibb to Present New Data Advancing Research Across Serious Liver Diseases At The Liver Meeting 2017
10/20/2017
Bristol-Myers Squibb Company today announced that new data across serious liver diseases, including nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), will be presented at The Liver Meeting 2017 in Washington, DC, October 20 - 24, 2017.
-
FDA Accepts Bristol-Myers Squibb's Application For Opdivo (Nivolumab) In Patients With Resected High-Risk Advanced Melanoma And Grants Priority Review
10/17/2017
Bristol-Myers Squibb Company announced today that FDA has accepted for priority review its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.
-
Bristol-Myers Squibb Release: Opdivo Alone Or Combined With Yervoy In Exploratory Analysis From Phase I/II Study Checkmate -032
10/17/2017
Bristol-Myers Squibb Company today announced data evaluating Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) from the Phase 1/2 CheckMate -032 trial.